# A Study to Test DSP107 in Combination With Atezolizumab in Comparison With Fruquintinib as a New Treatment for Colorectal Cancer.

> **NCT07235293** · PHASE2 · RECRUITING · sponsor: **Kahr Bio Australia Pty Ltd** · enrollment: 90 (estimated)

## Conditions studied

- Colorectal Cancer

## Interventions

- **DRUG:** DSP107 + Atezolizumab
- **DRUG:** Fruquintinib

## Key facts

- **NCT ID:** NCT07235293
- **Lead sponsor:** Kahr Bio Australia Pty Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-01-16
- **Primary completion:** 2026-09-30
- **Final completion:** 2027-04-30
- **Target enrollment:** 90 (ESTIMATED)
- **Last updated:** 2026-04-09

## Collaborators

- Novotech (Australia) Pty Limited

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07235293

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07235293, "A Study to Test DSP107 in Combination With Atezolizumab in Comparison With Fruquintinib as a New Treatment for Colorectal Cancer.". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07235293. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*